These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2785847)

  • 1. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
    Sirotnak FM; Schmid FA; DeGraw JI
    Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localized chemotherapy of Gardner's lymphosarcoma of C3H mice using combinations of carrier-sorbed antifolics and detoxicating tetrahydrofolates.
    Motycka K; Slavík K; Balcarová A; Spacek P; Kubín M
    Czech Med; 1981; 4(1-2):14-24. PubMed ID: 6973453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models.
    Sirotnak FM; Schmid FA; Otter GM; Piper JR; Montgomery JA
    Cancer Res; 1988 Oct; 48(20):5686-91. PubMed ID: 3167828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
    Khokhar NZ; She Y; Rusch VW; Sirotnak FM
    Clin Cancer Res; 2001 Oct; 7(10):3199-205. PubMed ID: 11595715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice.
    Sirotnak FM; DeGraw JI; Moccio DM; Dorick DM
    Cancer Treat Rep; 1978 Jul; 62(7):1047-52. PubMed ID: 688246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.
    Samuels LL; Moccio DM; Sirotnak FM
    Cancer Res; 1985 Apr; 45(4):1488-95. PubMed ID: 3978616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
    Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
    Brown DH; Braakhuis BJ; van Dongen GA; van Walsum M; Bagnay M; Snow GB
    Anticancer Res; 1989; 9(6):1549-52. PubMed ID: 2627109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
    Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI
    NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
    Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
    Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.